Vanda Pharmaceuticals (VNDA) Change in Cash (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Change in Cash data on file, last reported at -$30.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 425.07% year-over-year to -$30.8 million; the trailing twelve-month figure through Mar 2026 stood at -$57.8 million (down 332.29% YoY), and the FY2025 full-year result was -$17.5 million, up 47.87% from the prior year.
• Change in Cash declined to -$30.8 million in Q1 2026, from $14.8 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $219.1 million in Q1 2023 to a low of -$204.1 million in Q2 2023.
• A 5-year average of $112529.4 and a median of -$8.7 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash surged 5428.21% in 2022 and sank 2245.63% in 2023, its largest moves.
• Tracing VNDA's Change in Cash over 5 years: stood at $85.6 million in 2022, then tumbled by 155.31% to -$47.4 million in 2023, then soared by 103.84% to $1.8 million in 2024, then soared by 715.23% to $14.8 million in 2025, then slumped by 307.82% to -$30.8 million in 2026.
• Business Quant data shows VNDA's Change in Cash at -$30.8 million in Q1 2026, $14.8 million in Q4 2025, and -$11.0 million in Q3 2025.